PMFA
ABUS icon

Plante Moran Financial Advisors’s Arbutus Biopharma ABUS Stock Holding History

Plante Moran Financial Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,000
Closed -$4K – 858
2022
Q3 		$4K Hold
2,000
– – ﹤0.01% 713
2022
Q2 		$5K Hold
2,000
– – ﹤0.01% 700
2022
Q1 		$6K Hold
2,000
– – ﹤0.01% 644
2021
Q4 		$8K Buy
+2,000
New +$7.77K ﹤0.01% 712

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Plante Moran Financial Advisors's ABUS Position: Q4 2022 in Review

Plante Moran Financial Advisors sold out of Arbutus Biopharma (ABUS) in Q4 2022, closing a stake of 2,000 shares — an estimated $4K sold.

Plante Moran Financial Advisors first reported a position in ABUS in Q4 2021 and held it in 4 quarters. The position peaked at $8K in Q4 2021. 114 funds tracked by Wall St. Rank hold ABUS as of Q4 2022.

  • Plante Moran Financial Advisors reported no remaining Arbutus Biopharma position as of Q4 2022 after selling out during the quarter.
  • Plante Moran Financial Advisors sold 2,000 Arbutus Biopharma shares in Q4 2022, an estimated $4K.
  • Plante Moran Financial Advisors first reported a position in Arbutus Biopharma in Q4 2021 and held it in 4 quarters.
  • Plante Moran Financial Advisors's Arbutus Biopharma position peaked at $8K in Q4 2021.
  • 114 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2022.

Based on Plante Moran Financial Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.